Key facts
- This page summarizes Wilhelmus Cm Groenhuysen's Form 4 filing for NovoCure Ltd (NVCR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Aug 2024, 16:21.
Wilhelmus Cm Groenhuysen - 28 Jun 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- NVCR
- Reported as of
- 28 Jun 2024
- Net transaction value
- +$12,913
- SEC form
- 4
- Accepted by SEC
- 06 Aug 2024, 16:21:21 UTC
- Prior SEC filing
- 07 Jun 2024
- Next SEC filing
- 21 May 2025
- Source filing
- View source filing
- Reporting owner signature
- Steven Robbins, as attorney in fact for Groenhuysen, Wilhelmus CM
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wilhelmus Cm Groenhuysen filed Form 4 for NovoCure Ltd (NVCR) on 06 Aug 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2024.
- Current net transaction value: +$12,913.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVCR
transaction
Ordinary Shares
Award
- Transaction value
- $12,913
- Shares
- +1,055
- Change %
- +0.42%
- Price
- $12.24
- Shares after
- 252,290
- Date
- 28 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
Footnote F2
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.